Dosing and Administration RTU

THE FIRST AND ONLY FDA-APPROVED ENALAPRIL ORAL SOLUTION

  • Trusted efficacy delivered with consistent potency.1
  • No need to crush or compound tablets into a liquid formulation.
  • Titrate to the appropriate dose as needed for blood pressure control.

Weight-based dosing for pediatric hypertension in patients over 1 month of age
The recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily.
  • Dosage should be adjusted according to blood pressure response.
  • Doses above 0.58 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients.
  • Epaned is not recommended in neonates (i.e., infants 1 month of age or less), preterm infants who have not reached a corrected post-conceptual age of 44 weeks, and 
in pediatric patients with glomerular filtration rate <30 mL/min/1.73 2.

Dosing for adult hypertension
  • The recommended starting dosage is 5 mg daily up to a maximum of 40 mg daily as needed to help achieve blood pressure goals.
  • See full Prescribing Information for additional information for dosage adjustment for renal impairment and use with diuretics.


  • Dosing for adults with cardiac conditions
    The recommended starting dose is 2.5 mg twice daily up to a maximum of 20 mg twice daily for symptomatic heart failure and up to a maximum of 10 mg twice daily for asymptomatic left ventricular dysfunction. See full Prescribing Information for additional information.

    Oral solution for consistent dosing and convenience1,2
    • Before dispensing: keep refrigerated (2–8° C, 36–46° F).
    • After dispensing: can be stored at room temperature (20–25° C, 68–77° F) for up to 60 days.
    • Keep lid tightly closed. Avoid freezing and excessive heat.
    • No shaking necessary prior to administration.
    • Keep this and all medication out of the reach of children.
     

    See why Epaned is an affordable, accessible choice.  

    References: 1. Epaned Oral Solution [prescribing information]. Greenwood Village, CO: Silvergate Pharmaceuticals, Inc.; 2016. 2. Data on file, Silvergate Pharmaceuticals, Inc.; 2016.